How should buyers structure procurement contracts in the Computational Biology Market?

Tie payment to validated deliverables rather than seat counts. Include data-portability clauses and audit-trail requirements upfront, since regulatory qualification makes platform migration costly later [11]. Read More

What integration challenges most often derail deployments?

Connector development between legacy laboratory information systems and modern analysis pipelines consumes the largest share of overrun budgets. Insist that vendors demonstrate live integration with your existing repositories before contract signature [12]. Read More

Do open-source tools compete meaningfully with commercial platforms?

Yes for exploratory research, rarely for regulatory submissions. Commercial vendors sell validation documentation and support liability, which open-source projects cannot provide [14]. Read More

Which insurance and liability issues apply to computational evidence?

Sponsors retain full regulatory liability for model outputs regardless of vendor. Negotiate indemnification for software defects, and verify the vendor maintains version-locked archives of any model used in a submission [1]. Read More

How does the Computational Biology Market differ for agricultural versus pharmaceutical buyers?

Agricultural users prioritise throughput on large population datasets at low per-sample cost. Pharmaceutical buyers pay premiums for regulatory traceability instead [19]. Read More

What skills should an internal team have before licensing an enterprise platform?

At minimum, one workflow engineer and one domain scientist who can interpret model uncertainty. Without both, organisations under-use expensive licences [13]. Read More

Is vendor lock-in a material risk in the Computational Biology Market?

Considerable, particularly where proprietary data formats and qualified model states are involved. Require export in open standards as a contractual condition [12]. Read More

Computational Biology Market (2026 - 2035)

ID: MRFR/HS/7744-HCR 100 Pages Rahul Gotadki Last Updated: October 22, 2026

Computational Biology Market Research Report: Size, Share, Trend Analysis By Applications (Drug Discovery, Genomics, Proteomics, Metabolomics, Systems Biology), By Solution Type (Software, Hardware, Services), By Deployment Mode (On-Premises, Cloud-Based), By End Users (Pharmaceutical Companies, Biotechnology Firms, Academic Institutions, Research Organizations), By Technology (Algorithm Development, Data Analysis, Modeling & Simulation, High-Performance Computing) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2026 To 2035

Computational Biology Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)13.5%

2025 Market SizeUSD 7.71 Billion

2035 Market SizeUSD 27.22 Billion

Key Players

Dassault Systèmes

Certara

Schrödinger

Siemens

Thermo Fisher Scientific

Illumina

Trends

Multi-Omics Data Volume Growth
Foundation Models Reshaping Prediction
Regulatory Legitimisation of In-Silico Evidence

Opportunities

Regulator-Ready Model Qualification as a Service
Emerging-Market Genomics Build-Out
Federated Data Monetisation

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Application |
2. 2.2 By Tool and Service |
3. 2.3 By Geography
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Multi-Omics Data Volume Growth |
2. 4.2 Foundation Models Reshaping Prediction |
3. 4.3 Regulatory Legitimisation of In-Silico Evidence |
4. 4.4 Compute Supply Meeting Biological Demand
5 Restraints Impact Analysis |
1. 5.1 Interoperability and Standards Fragmentation |
2. 5.2 Talent Supply Constraints |
3. 5.3 Model Validation and Reproducibility Costs
6 Opportunities |
1. 6.1 Regulator-Ready Model Qualification as a Service |
2. 6.2 Emerging-Market Genomics Build-Out |
3. 6.3 Federated Data Monetisation |
4. 6.4 Digital Twins for Bioprocess Manufacturing |
5. 6.5 Toxicology Substitution Contracts
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Autonomous Discovery Loops |
2. 8.2 Platform Economics and Consolidation |
3. 8.3 Sovereign Compute and Data Localisation |
4. 8.4 Clinical Translation and Reimbursement
9 Market Segmentation Analysis |
1. 9.1 By Application | |
  1. 9.1.1 Cellular and Biological Simulation | |
  2. 9.1.2 Drug Discovery and Disease Modelling | |
  3. 9.1.3 Preclinical Drug Development | |
  4. 9.1.4 Clinical Trials and Human Body Simulation |
2. 9.2 By Tool | |
  1. 9.2.1 Databases | |
  2. 9.2.2 Analysis Software and Services | |
  3. 9.2.3 Infrastructure and Hardware |
3. 9.3 By Service | |
  1. 9.3.1 In-House | |
  2. 9.3.2 Contract / Outsourced |
4. 9.4 By End-User | |
  1. 9.4.1 Academics | |
  2. 9.4.2 Industry and Commercial | |
  3. 9.4.3 Government and Regulatory
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Dassault Systèmes | |
  2. 10.3.2 Certara | |
  3. 10.3.3 Schrödinger | |
  4. 10.3.4 Siemens (Dotmatics) | |
  5. 10.3.5 Thermo Fisher Scientific | |
  6. 10.3.6 Illumina | |
  7. 10.3.7 Simulations Plus | |
  8. 10.3.8 Genedata | |
  9. 10.3.9 Chemical Computing Group | |
  10. 10.3.10 Insilico Medicine | |
  11. 10.3.11 Instem
11 Recent News & Developments
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Valuation Currency & Unit |
3. 12.3 CAGR Driver Disclaimer
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Computational Biology Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Computational Biology Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 6 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 7 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 8 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 9 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 10 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 11 Global Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 12 Global Market Size, by Tool, 2021–2035 (USD Billion) |
TABLE 13 Global Market Size, by Service, 2021–2035 (USD Billion) |
TABLE 14 Global Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 15 North America Market Size, by Application, 2021–2035 (USD Billion) |
TABLE 16 Europe Market Size, by Tool, 2021–2035 (USD Billion) |
TABLE 17 Asia-Pacific Market Size, by End-User, 2021–2035 (USD Billion) |
TABLE 18 Competitive Benchmarking Matrix, 2026 |
TABLE 19 Company Profiles — Key Players |
TABLE 20 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 21 Report Scope & Methodology Summary |
TABLE 22 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics — Drivers, Restraints and Opportunities Snapshot |
FIGURE 2 Industry Value Chain Analysis |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Curve, 2022–2035 |
FIGURE 6 Application Segment Share, 2025 vs 2035 |
FIGURE 7 Tool Segment Share, 2025 vs 2035 |
FIGURE 8 Service Model Split, 2025 vs 2035 |
FIGURE 9 End-User Segment Share, 2025 vs 2035 |
FIGURE 10 Regional Revenue Share, 2025 |
FIGURE 11 Regional CAGR Comparison, 2026–2035 |
FIGURE 12 Country-Level Growth Heat Map, 2026–2035 |
FIGURE 13 Competitive Landscape Positioning Quadrant, 2026 |
FIGURE 14 Vendor Revenue Share Distribution, 2025 |
FIGURE 15 Technology Adoption S-Curve, 2021–2035

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Application	Cellular and Biological Simulation; Drug Discovery and Disease Modelling; Preclinical Drug Development; Clinical Trials and Human Body Simulation	Cellular and Biological Simulation	Drug Discovery and Disease Modelling
By Tool	Databases; Analysis Software and Services; Infrastructure and Hardware	Databases	Analysis Software and Services
By Service	In-House; Contract / Outsourced	Contract / Outsourced	In-House
By End-User	Academics; Industry and Commercial; Government and Regulatory	Academics	Industry and Commercial
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Application

Sub-Segment	Key Trend
Cellular and Biological Simulation	Pathway-level digital twins replacing static network diagrams
Drug Discovery and Disease Modelling	Structural prediction compressing hit-identification timelines
Preclinical Drug Development	Physiologically based pharmacokinetic models entering regulatory submissions
Clinical Trials and Human Body Simulation	Virtual control arms reducing recruitment burden in rare-disease studies

Application demand splits cleanly between breadth and intensity. Simulation workloads support the widest user base, while discovery and preclinical modelling attract the highest revenue per account because sponsors link them directly to pipeline decisions.

By Tool

Sub-Segment	Key Trend
Databases	Subscription curation shifting toward federated, access-controlled models
Analysis Software and Services	Managed pipelines displacing self-maintained toolchains
Infrastructure and Hardware	GPU tenancy replacing capital purchase of on-premise clusters

Tooling spend is migrating from assets to outcomes. Buyers increasingly accept bundled compute inside software contracts, which simplifies budgeting and transfers infrastructure risk to the vendor.

By Service

Sub-Segment	Key Trend
In-House	Large sponsors internalising platforms once regulatory qualification is achieved
Contract / Outsourced	Specialist providers absorbing variable analytical load from mid-tier biotechs

Outsourcing dominates today because talent is scarce and project load is lumpy. Internalisation grows faster among the largest sponsors, who reach the volume threshold where owning the capability beats renting it.

By End-User

Sub-Segment	Key Trend
Academics	Grant-funded adoption sustaining the widest installed licence base
Industry and Commercial	Pipeline productivity pressure driving premium platform spend
Government and Regulatory	Review agencies and surveillance networks building internal modelling capacity

Academic users establish tool familiarity that follows researchers into industry, giving vendors a low-cost acquisition channel. Commercial accounts convert that familiarity into support contracts, multi-year renewals, and the bulk of realised revenue.

By Region

Sub-Segment	Key Trend
North America	Regulatory qualification pathways anchoring premium pricing
Europe	Data-residency requirements shaping architecture and vendor selection
Asia-Pacific	State-funded supercomputing and population genomics driving fastest growth
South America	Cloud consumption pricing removing capital-expenditure barriers
Middle East & Africa	Sovereign genome programmes and pathogen surveillance creating greenfield demand

Geographic performance follows funding architecture more than population. Where public money underwrites data generation, commercial analysis demand reliably follows within two to three years.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”